微粒化纯化黄酮组分对早期慢性静脉疾病C0s-C1期的疗效:系统评价与Meta分析
该系统评价与Meta分析纳入5项前瞻性研究共411例C0s-C1期慢性静脉疾病患者,评估每日口服MPFF 1000 mg的疗效。结果显示MPFF显著减轻疼痛和沉重感并改善生活质量,支持将其用于早期疾病管理。
要点
- MPFF可显著减轻C0s-C1期患者的腿部疼痛和沉重感。
- MPFF可改善早期慢性静脉疾病患者的生活质量。
- 证据支持在早期慢性静脉疾病管理中采用MPFF治疗。
核心结论
- 本Meta分析强化了MPFF缓解C0s-C1期患者腿部静脉症状和改善生活质量的证据,支持将其用于早期疾病管理。
研究设计与样本
- 遵循PRISMA指南的系统评价与Meta分析,检索MEDLINE、Embase和Cochrane数据库自建库至2023年11月。
- 纳入评估MPFF(每日口服1000 mg)用于C0s-C1期患者的前瞻性研究(随机对照试验及比较性、单臂和观察性研究)。
- 共分析5项研究、411例患者,平均年龄40.1(8.0)岁,96.6%为女性,C1期占80%、C0s期占20%。
- 数据采用随机效应Meta分析模型分析。
主要发现
- MPFF显著降低疼痛强度(平均变化-2.3 cm;95%CI -3.1至-1.6)。
- MPFF显著减轻沉重感(平均变化-2.8 cm;95%CI -3.5至-2.1)。
- MPFF显著改善生活质量(平均变化-16.0;95%CI -20.7至-11.3)。
- 两项研究报告症状完全缓解率:疼痛100.0%、沉重感87.9%、抽筋97.8%。
临床怎么用
- 对于C0s-C1期慢性静脉疾病患者,可考虑使用MPFF每日口服1000 mg以缓解腿部静脉症状并改善生活质量。
局限性
- 两项研究存在高偏倚风险。
- 研究间异质性水平常较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Chronic venous disease is a progressive disease that often begins with venous symptoms even without visible signs. This systematic review and meta-analysis aimed to evaluate the effectiveness of micronized purified flavonoid fraction (MPFF) in patients with early stage chronic venous disease (Clinical, Etiological, Anatomical, and Pathophysiological C0s-C1). METHODS: A systematic search was conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analysis guidelines. MEDLINE, Embase, and Cochrane databases were searched from inception until November 2023. Prospective studies (randomized controlled trials and comparative, single-arm, and observational studies) assessing MPFF (1000 mg daily orally) in C0s-C1 patients were included. Outcomes included leg venous symptoms (pain, heaviness, and cramps) and quality of life (QoL). The data were analyzed using a random-effects meta-analysis model. RESULTS: Five studies involving 411 patients were analyzed. The patients' mean age was 40.1 (8.0) years, and 96.6% of them were female. Patients were classified as Clinical, Etiological, Anatomical, and Pathophysiological C1 (80%) and C0s (20%). MPFF significantly reduced pain intensity (mean change [MC], -2.3 cm; 95% confidence interval [CI], -3.1 to -1.6), reduced heaviness (MC, -2.8 cm; 95% CI, -3.5 to -2.1), and improved QoL (MC, -16.0; 95% CI, -20.7 to -11.3). Two studies reported complete resolution of symptoms for pain (100.0%), heaviness (87.9%), and cramps (97.8%). Two studies had a high risk of bias, and the heterogeneity level was frequently high among studies. CONCLUSIONS: The present meta-analysis reinforces the evidence supporting MPFF effectiveness in alleviating venous leg symptoms and improving QoL in C0s-C1 patients and supports the use of MPFF treatment in early disease management.
引用
- Eliete B, Igor Z, Miguel A, et al. Effectiveness of micronized purified flavonoid fraction in early stage chronic venous disease-Clinical, Etiological, Anatomical, and Pathophysiological C0s-C1: A systematic review and meta-analysis. J Vasc Surg Venous Lymphat Disord. 2026. PMID: 42331095. doi:10.1016/j.jvsv.2026.102558
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。